Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models

Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models

Neuroinflammation significantly contributes to the pathophysiology of several neurodegenerative diseases. This is also the case in glaucoma and may be a reason why many patients suffer from progressive vision loss despite maximal reduction in intraocular pressure. Pioglitazone is an agonist of the p...

Full description

Bibliographic Details
Main Authors: Huilan Zeng, Alina V. Dumitrescu, David Wadkins, Benjamin W. Elwood, Oliver W. Gramlich, Markus H. Kuehn
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Biomolecules
Subjects:
glaucoma
PPARγ
pioglitazone
glucose metabolism
Online Access:https://www.mdpi.com/2218-273X/12/2/281

Similar Items

Similar Items